Development of a potent melanoma vaccine capable of stimulating CD8+ T-cells independently of dendritic cells in a mouse model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2015-04-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-015-1695-3PMID 25893808PMCID PMC11028525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines

  2016cited by this paper
• Current State of Animal (Mouse) Modeling in Melanoma Research

  2015cited by this paper
• Proof of Principle

  2014cited by this paper
• Dendritic cells and cancer immunotherapy.

  2014cited by this paper
• Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study

  2014cited by this paper
• Epidemiology, risk factors, prevention, and early detection of melanoma.

  2014cited by this paper
• A Global Review of Melanoma Follow-up Guidelines.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Historical review of melanoma treatment and outcomes.

  2013cited by this paper
• Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

  2012cited by this paper
• HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

  2011cited by this paper
• Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

  2010cited by this paper
• Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

  2010cited by this paper
• Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine

  2009cited by this paper
• Immunotherapy for advanced melanoma.

  2008cited by this paper
• An Update on Malignant Melanoma Vaccine Research

  2007cited by this paper
• Dendritic cell immunotherapy for stage IV melanoma

  2007cited by this paper
• Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?

  2006cited by this paper
• Dendritic-cell-based therapeutic vaccination against cancer.

  2005cited by this paper
• Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine

  2003cited by this paper
• Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.

  2003cited by this paper
• Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

  2003cited by this paper
• Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells

  2003cited by this paper
• Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

  2002cited by this paper
• Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

  2001cited by this paper
• Origin and differentiation of dendritic cells.

  2001cited by this paper
• Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.

  2000cited by this paper
• Clinical significance of defective dendritic cell differentiation in cancer.

  2000cited by this paper
• The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues

  1999cited by this paper
• Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.

  1999cited by this paper
• Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway

  1998cited by this paper
• Decreased antigen presentation by dendritic cells in patients with breast cancer.

  1997cited by this paper
• Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

  1997cited by this paper
• Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.

  1996cited by this paper
• Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

  1996cited by this paper
• [Phase II study].

  1995cited by this paper
• Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin.

  1994cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones

  1993cited by this paper
• Mice lacking MHC class II molecules.

  1991cited by this paper
• The dendritic cell system and its role in immunogenicity.

  1991cited by this paper

• Evaluation of an F Protein-Based Recombinant Protein for Immunization Against Respiratory Syncytial Virus

  2025cites this paper
• Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants

  2019influential citation
• A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance.

  2018cites this paper
• Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

  2017cites this paper
• Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines

  2016cites this paper
• Current State of Animal (Mouse) Modeling in Melanoma Research

  2015cites this paper